Trials / Completed
CompletedNCT02216188
Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity
Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Affiris AG · Industry
- Sex
- All
- Age
- 40 Years – 68 Years
- Healthy volunteers
- Not accepted
Summary
This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® PD01A vaccinations in patients with Parkinson's disease. Patients, who have already participated in AFF008 will be involved and will be receive one boost immunization with AFFITOPE® PD01A. One study site in Vienna (Austria) will be involved. In addition, up to 8 patients will be offered participation within an untreated control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFFITOPE® PD01A | s.c. injection |
| OTHER | Control | Untreated control group |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-08-01
- First posted
- 2014-08-13
- Last updated
- 2015-08-17
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT02216188. Inclusion in this directory is not an endorsement.